Candel Therapeutics Inc

CADL is in a Stage 2 advancing phase with a bullish medium-term bias anchored by rising EMAs and an active Parabola pattern. Price is currently extended and extreme overbought, making short-term timing unfavorable. Under a speculative strategy, we defer execution and await a controlled pullback into the 9/21 EMA zone for a higher-probability entry.

• ↑39% disease-free survival improvement vs placebo; BLA planned Q4 2026
• ↑Mark Sims CCO hire strengthens oncology commercialization strategy
• ↓Negative earnings yield and weak profitability challenge cash runway